AstraZeneca announces availability of Saxa / Dapa FDC in UK
UK-based AstraZeneca has announced the availability of Qtern for adult patients with type 2 diabetes in the country. Quern is a fixed dose combination of saxagliptin and dapagliflozin. The tablet received marketing authorization from the European Commission on 19 July last year and is indicated in adults aged 18 and older with type 2 diabetes in order to improve glycemic control. The European Commission approved the tablet based on data from three Phase III randomised.
Saxa / dapa FDC can be used in patients with mild renal impairment and should be avoided in patients with moderate-to-severe renal impairment.
Trivitron launches its digital radiography system Ultisys at Arab Health 2017
Trivitron Healthcare’s radiology division Kiran Medical Systems has now introduced its innovation driven Ultisys range of radiography products during the Arab Health Convention in Dubai. Ultisys offers an affordable yet versatile platform for a wide range of clinical applications involving general radiography.
Kiran’s portfolio of radiology products includes the Infinity and Elite series surgical C-Arm systems available in 3.5kW and 5.0kW power output and the option of 1Kx1K digital imaging chain with advanced image processing capabilities.
BrainStorm Cell Therapeutics validates NurOwn Cryopreservation
Brainstorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has validated its cryopreservation process for NurOwn in preparation for the upcoming phase 3 clinical study in amyotrophic lateral sclerosis (ALS).
The validation involved a comparison of NurOwn (MSC-NTF cells) derived from fresh mesenchyme stem cells (MSC) to those derived from cryopreserved MSC. Company scientists were successful in showing that the MSC can be stored in the vapour phase of liquid nitrogen for prolonged periods of time while maintaining their characteristics.
NEI scientists identify stem cell secretions may protect against glaucoma
A new study in rats shows that stem cell secretions, called exosomes, appear to protect cells in the retina, the light-sensitive tissue in the back of the eye. The findings, published in Stem Cells Translational Medicine, point to potential therapies for glaucoma, a leading cause of blindness in the United States. The study was conducted by researchers at the National Eye Institute (NEI), part of the National Institutes of Health (NIH).